glp-1 side effect lawsuit in michigan Georgia woman part of claiming link between weight loss drugs and blindness – WSB-TV Channel 2 Semaglutide, a glucagon-like peptide-1 (GLP-1)

Start low to gauge nausea/flushing

It is possible that not all commenters reviewed this year's rule in detail, and it is also possible that some reviewers chose not to comment on the proposed rule

Response: Although we acknowledge the applicant's concerns regarding the descriptor for C1739, we do not agree that the device category code should be withdrawn and replaced with a new code effective January 1, 2026, for the following reasons: First, per the applicant's request prior to CY 2026 rulemaking, CMS revised the descriptor for C1739 to read, effective October 1, 2025: Tissue marker, uniquely detectable and identifiable with probe/sensor, any method (implantable), with delivery system

Within days I felt more active and my skin looked fresh